Friday, July 10, 2026

pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis

Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
Clinical program

Pimavanserin

Approved · small molecule · Insomnia Chronic

Pimavanserin for Insomnia Chronic is a Approved program (small_molecule) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).

← All Acadia Pharmaceuticals B.V. projects Approved small molecule terminated

Internal code H-48699

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Acadia Pharmaceuticals B.V.
Phase
Approved
Modality
small_molecule
Indication
Insomnia Chronic
Status
terminated
Trials
1